ArticleAlzheimer's & dementia (Amsterdam, Netherlands)
Plasma amyloid-β oligomerization tendency as a potential predictor for conversion from mild cognitive impairment to Alzheimer's dementia: Findings from the GMCII cohort.
Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Associations between plasma beta amyloid and cognitive decline: A systematic review and meta-analysis.Narra J · 2025Pooled it
- Systemic proteomic and organ aging signatures associated with plasma Aβ oligomerization in a Korean cohort: a cross-sectional study.Frontiers in aging neuroscience · 2026Article
- Plasma amyloid-β oligomerization tendency as a potential predictor for conversion from mild cognitive impairment to Alzheimer's dementia: Findings from the GMCII cohort.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study aimed to explore the association between plasma amyloid-β oligomerization tendency (OAβ) and cognitive performance in Alzheimer's disease (AD) and determine its predictive value for outcomes of mild cognitive impairment (MCI).
methodsPlasma from 727 subjects (286 AD, 260 MCI, and 181 controls) in a case registry was analyzed using the multimer detection system (MDS) to measure plasma OAβ.
resultsElevated plasma OAβ was strongly correlated with multidomain cognitive performance in patients with MCI and AD. Patients with MCI with high baseline plasma OAβ demonstrated a higher risk of progressing to dementia (hazard ratio = 1.083, 95% confidence interval [CI] 1.032-1.137). Baseline plasma OAβ effectively predicted MCI-dementia conversion (area under the curve [AUC] = 0.824, 95% CI 0.752-0.897). DISCUSSION: The real-world findings underscore the clinical relevance of plasma OAβ as a potential predictor for the conversion from mild cognitive impairment (MCI) to dementia. Highlights: We recruit study participants of Alzheimer's dementia (AD), mild cognitive impairment (MCI), and cognitively normal controls in a case registry.We use the multimer detection system (MDS) to measure plasma amyloid-β oligomerization tendency (OAβ).We observe that elevated plasma OAβ strongly correlates with multidomain cognitive performance in patients with MCI and AD.MCI individuals with high baseline plasma OAβ demonstrate a higher risk of progressing to dementia.The real-world findings underscore the clinical relevance of plasma Oaβ as a potential predictor for the conversion from MCI to dementia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.